Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
A few Exemplary Chinese Dishes, Which Are Famous Around the world - 2Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
- 3Meet the Stars of the Feline World: Well known Pet Feline Varieties
- 4The Manual for Electric Vehicles that will be hot dealers in 2023
- 5US FDA approves Kura-Kyowa's blood cancer therapy
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- Don't plan to cook on Thanksgiving? Here are the restaurants and fast food places that are scheduled to be open
- Lilly, Novo lock horns in India's obesity drug race
- This ‘CSI: Miami’ star spent years solving crimes on TV. Then she became the target of one herself.
- Astonishing Deserts All over The Planet You Really want To Visit
- African nations push to recognize crimes of colonialism in Algeria
- Cells have more mini ‘organs’ than researchers thought − unbound by membranes, these rogue organelles challenge biology’s fundamentals
- Decrease in Home Buy Credits and Home loan Renegotiating Rates: An Outline of Latest things
- Brazil's agricultural research agency gets cannabis research greenlight
